In Vitro Diagnostics (IVD) include reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. The reagents, instruments and systems are used in the collection, preparation, and examination of specimens taken from the human body. This includes Cardiac Disease, Hematological Disorders, Hormonal Disorders, Metabolic Disorder, Infectious Disease, IVD Analyzers, Oncology and Reproductive Health Diagnostics. A Cardiac Marker Test is a biomarker test used to diagnose a cardiac disease event or predict the likelihood of cardiac disease through the measurement of Troponin, Brain Natriuretic Peptide, Creatine Kinase Myocardial Band (CK-MB) , and other target molecules. GlobalData uses proprietary data and analytics to provide a comprehensive report on the cardiac marker tests market in Canada. Buy the latest report here.
Smarter leaders trust GlobalData
In 2023, GlobalData’s Market Model methodology determined that the leading player in the cardiac marker tests market in Canada was F. Hoffmann-La Roche followed by Abbott Laboratories, Quidelortho, Siemens Healthineers, Danaher and bioMerieux.
Understanding market size can be crucial to evaluate opportunities and make informed decisions about market entry and exit. Medical device companies can identify attractive segments in respective markets as well as develop marketing strategies based on forecasts for those segments.
Cardiac Marker Tests are categorized into lab-based biomarker and point of care biomarker tests. Laboratory Tests: Any tests that require transporting of patient samples to a laboratory, including those with rapid turnaround times, are defined as laboratory or lab-based tests. For this Cardiac Marker Tests, lab-based tests include laboratory troponin tests, laboratory BNP tests, and CK-MB laboratory tests. Point Of Care Tests: Point of Care Testing (POC) is defined as medical diagnostic testing performed outside the clinical laboratory in close proximity to where the patient is receiving care. POC is typically performed by non-laboratory personnel and the results are used for clinical decision making. These devices range from manual methods to automated analyzers and are often handheld or compact portable analyzers. For this Cardiac Marker Tests, POC tests include POC Troponin Tests, POC BNP tests, and other POC Tests.
The cardiac marker tests market in Canada can expand or contract due to a variety of reasons including population demographics, disease incidence and prevalence, macroeconomic issues, and geopolitical considerations. Disruption to a market could be caused by a sudden, unexpected change in these factors, but it could also be driven by changes in clinical practice, leading to a change in diagnosis or treatment of patients, as part of a process to generally improve medical practice.
For the latest analysis of the market size cardiac marker tests in Canada, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Medical Intelligence Center Market Models are the gold standard of medical device market valuation, company share estimation and market trend forecasting. GlobalData uses a patient-based forecast model or installed base methodology to determine the market size for therapeutic indications and capital equipment expenditures. Estimates are based on a number of sources, including primary research—KOL and industry contact interviews—and secondary research, such as company reports, press releases, published articles, proprietary databases, and general news media.
